Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous nivolumab with or without rHuPH20 in advanced solid tumors
NL-OMON59842Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), melanoma and 3 more (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Serum nivolumab Cmax, Serum nivolumab Tmax and 3 more. Started May 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanomahepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON59842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59842.